Inquiry Basket
CAS No.: 1059588-19-0
Cat No.: BADC-00884
Purity: ≥95%
4.5 
m-PEG8-Ms is a mesylate-activated PEG linker used in antibody-drug conjugates for efficient nucleophilic substitution reactions. Its PEG8 spacer increases hydrophilicity and solubility of payloads, improving bioconjugate stability and pharmacokinetic profiles in targeted therapies.
Structure of 1059588-19-0
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
m-PEG8-Ms, a polyethylene glycol derivative widely utilized in biochemical and pharmaceutical realms, finds diverse applications.
Drug Delivery Systems: In the realm of drug delivery, m-PEG8-Ms plays a pivotal role in enhancing the solubility and stability of pharmaceuticals. By conjugating polyethylene glycol chains to drug molecules, it elevates their bioavailability and extends their circulation time within the bloodstream.
Protein Conjugation: Within the domain of protein chemistry, m-PEG8-Ms is a cornerstone for pegylation, a process involving the attachment of PEG moieties to proteins. This innovative procedure serves to diminish immunogenicity and prolong the half-life of therapeutic proteins and peptides.
Biocompatible Coatings: Leveraging the hydrophilic properties of PEG, m-PEG8-Ms finds application in forming biocompatible coatings on medical devices and implants. These coatings effectively mitigate protein adsorption and cell adhesion, thereby reducing the risk of immune responses and infections.
Nanoparticle Functionalization: For the functionalization of nanoparticles in diagnostic and therapeutic applications, m-PEG8-Ms emerges as a crucial player. By modifying nanoparticle surfaces with PEG chains, it enhances their stability and biocompatibility in biological settings, leading to the creation of nanoformulations tailored for targeted drug delivery and cutting-edge imaging technologies.
What is m-PEG8-Ms and its role in ADC linker design?
m-PEG8-Ms is a monomethoxy PEG linker terminated with a methanesulfonate leaving group. It enables selective conjugation to nucleophilic sites on antibodies, enhancing ADC solubility, stability, and reducing aggregation during conjugation.
25/10/2017
We would like to know how m-PEG8-Ms improves ADC performance.
The PEG8 spacer increases hydrophilicity and flexibility, reducing steric hindrance and preventing antibody aggregation. The methanesulfonate group facilitates efficient nucleophilic substitution reactions for stable ADC formation.
22/2/2019
Could you kindly advise which payloads are compatible with m-PEG8-Ms?
It can be conjugated to nucleophile-containing cytotoxins, peptides, or fluorophores. The PEG8 spacer maintains ADC solubility and enhances circulation half-life while preserving payload and antibody activity.
22/8/2021
Dear team, what are the recommended conjugation conditions for m-PEG8-Ms?
Conjugation is performed in slightly basic aqueous or mixed organic solvents (pH 7–8.5) under controlled temperatures to optimize reaction efficiency and maintain structural integrity of both antibody and payload.
9/9/2019
Good morning! What are the storage recommendations for m-PEG8-Ms to ensure long-term stability?
m-PEG8-Ms should be stored in a dry, low-temperature environment, protected from light and moisture. Use inert gas when possible to maintain chemical stability. Handling should follow safety precautions provided in the datasheet to avoid degradation. Full storage and handling instructions are included in the supporting documentation.
23/6/2016
— Dr. Matthew Green, Biochemist (UK)
m-PEG8-Ms provided excellent solubility and flexibility, improving linker accessibility.
22/8/2021
— Ms. Anna Weber, Senior Scientist (Germany)
High purity ensured smooth PEGylation and minimal side reactions.
23/6/2016
— Dr. Daniel Clark, ADC Development Scientist (USA)
Reproducible incorporation in multi-step ADC linker synthesis was achieved.
9/9/2019
— Dr. Sophie Laurent, Medicinal Chemist (France)
The reagent minimized steric hindrance, enhancing conjugation efficiency.
25/10/2017
— Dr. Lucas Meyer, Chemist (Germany)
m-PEG8-Ms enabled creation of extended PEG linkers for better solubility.
— Prof. Emily Wilson, Bioconjugation Specialist (UK)
m-PEG8-Ms from BOC Sciences facilitated seamless PEGylation with minimal side reactions. Documentation was clear, helping us optimize our workflow.
22/2/2019
m-PEG8-Ms
Required fields are marked with *
m-PEG8-Ms
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
